Skezi
SKEZI is a French health-data SaaS provider, spun out of AP-HP and Université Paris-Cité in 2020, offering a sovereign, HDS-certified platform (SKEZIA) for e-cohort management, PROMs/PREMs collection, and patient-reported research serving hospitals, academics, pharma, and patient associations.
- Company typePrivate
- Founded2020
- HeadquartersAnnecy, France
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Skezi does
SKEZI is a French health-data software company that provides a sovereign SaaS platform for collecting and valorising patient-reported health data, founded in December 2020 as a spin-off from Assistance Publique-Hôpitaux de Paris (AP-HP) and Université Paris-Cité. Its core product, SKEZIA, is a HDS-certified (Hébergeur de Données de Santé) platform hosted on French infrastructure that enables the creation and management of e-cohorts, customizable questionnaires, and routine collection of Patient-Reported Outcome Measures (PROMs) and Patient-Reported Experience Measures (PREMs), with API interoperability into hospital information systems. The portfolio has expanded through two acquisitions: SKEMEET (formerly ShareConfrère, acquired April 2023), a tele-expertise platform for expert consultations, multidisciplinary consensus meetings (eRCP) and rare-disease workflow; and Verbatim.Care (acquired December 2024), an NLP-based patient verbatim analysis platform. SKETHIS, launched in 2023, is positioned as France's first health-related quality-of-life observatory at population scale.
SKEZI serves five primary customer segments: patient associations and advocacy groups; academic researchers running e-cohorts; hospitals and healthcare institutions pursuing Value-Based Healthcare programmes; pharmaceutical and medical-device companies running patient-centred clinical or post-marketing studies; and individual healthcare professionals. Anchor customers and design partners include AP-HP and Université Paris-Cité (co-founders and the ComPaRe/ESPERES cohorts), INRAE (Le French Gut national microbiome project, targeting 100,000 volunteers by 2027), UCB Pharma (SPOON study on myasthenia gravis), and Biogen (NewPerSEPtion study on multiple sclerosis). The platform reports 600,000+ patients involved, 20M+ data points collected, and 60+ peer-reviewed scientific publications.
The business model combines SaaS subscriptions for the SKEZIA and SKEMEET platforms (with tiered service levels and the SKEZIA+ enhanced-service offering) and professional services for study design, regulatory compliance, and implementation. Distribution is hybrid: direct enterprise sales to hospitals, pharma and academic institutions, plus a self-serve free-beta access channel for smaller researchers, associations, and individual clinicians. The company is headquartered in Annecy with a Paris office, has 11–50 employees, and is privately held; the only disclosed funding event is a Bpifrance round of approximately $2.73M in November 2024, supplemented by EU co-funding.
Skezi firmographics
Firmographics- Name
- Skezi
- Legal name
- SKEZI
- Website
- https://skezi.eu
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- SKEZI is a French health-data SaaS provider, spun out of AP-HP and Université Paris-Cité in 2020, offering a sovereign, HDS-certified platform (SKEZIA) for e-cohort management, PROMs/PREMs collection, and patient-reported research serving hospitals, academics, pharma, and patient associations.
- Ownership category
- akta.pro rank
Skezi industry classification
Industry- Product category
- Clinical Research Software (Health Data Collection & E-Cohort Management)
- NAICS
- Scientific Research and Development Services (5417)
- SIC
- Services-Misc Health & Allied Services, Nec (8090)
- akta.pro primary industry
- eCOA/ePRO/eDiary & Patient-Facing Data Collection (HLACAOAB)
- akta.pro secondary industry
- Decentralized & Hybrid Trial Site Services (Home Health/Nursing) (HLAGACAH)
Keywords
Where Skezi is headquartered
LocationHeadquarters
- HQ city
- Annecy
- HQ country
- France
- HQ region
- Europe
Offices3 records
Markets served
Skezi business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
Revenue model
- Software Subscriptions (SKEZIA/SKEMEET): SaaS platform subscriptions for data collection, e-cohort management, and tele-expertise services with tiered service levels
- Professional Services: Expert support for study design, regulatory compliance, and implementation assistance for healthcare research projects
- SKEZIA+ Service: Enhanced service offering with individualized support for complex data collection projects
Go-to-market motion3 records
Distribution channels4 records
Marketing channels7 records
Skezi product offering
Product offeringCore offering
Skezi (commercial name: SKEZI) sells the SKEZIA SaaS platform, a sovereign French health data collection solution that enables clinical researchers, healthcare institutions, pharmaceutical companies, and patient associations to build and manage electronic patient cohorts (e-cohorts) and collect patient-reported outcomes (PROMs/PREMs) via customizable questionnaires. The company complements SKEZIA with SKEMEET tele-expertise software, SKETHIS quality-of-life observatory services, and Verbatim.Care NLP-based patient verbatim analysis.
Product overview
SKEZI offers a suite of e-health data collection solutions centered around its core platform SKEZIA. SKEZIA is the primary sovereign SaaS product for collecting secure health data via questionnaires, managing e-cohorts, and supporting PROMs/PREMs collection. This core platform is complemented by SKEMEET (formerly ShareConfrère), a tele-expertise platform for expert consultations and multidisciplinary meetings; Verbatim.Care, an NLP-powered patient verbatim analysis platform acquired from EntendsMoi; and SKETHIS, a quality-of-life observatory initiative. Together, these products form a 360° health data collection ecosystem spanning clinical research, routine care, patient experience, and public health monitoring.
Differentiator
Problem solved
Functional benefit
Brands
- SKEZIA: Platform for collecting sensitive and secure health data via questionnaires, including e-cohort management and survey tools.
- SKEMEET
- SKETHIS
- Verbatim.Care
Quantifiable outcome
- 600,000+ patients involved in platform studies
- +3 more outcomes
Companies that use Skezi
Customer profileNamed customers7 records
Segments5 records
Ideal customer profiles3 records
Skezi technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature5 records
Skezi partnerships and signals
Strategic signalPartnerships
16 partnerships are on record, tiered core, strategic and minor.
- INRAEcoreSKEZI deploying SKEZIA for Le French Gut national project, aiming to collect microbiome samples and data from 100,000 volunteers by 2027 to map French gut microbiota and understand chronic disease interactions
- Université Paris-CitécoreCo-founding partner of SKEZI spin-off, continuing development of ComPaRe cohort technology and academic research collaboration
- WithingsstrategicPartnership for remote patient monitoring combining Withings connected health devices with SKEZI data collection platform for hypertension management, enabling pharmacists to relay patient data
- OVHcloudstrategicSKEZI joined OVHcloud Startup Program for one year, receiving infrastructure support and recognition as Health Startup of the Year 2022
- OctopizestrategicPartnership for data anonymization using Octopize's unique technology to protect SKETHIS community data while preserving useful information for research
- Hack Your CareminorPartnership for recruiting professionals with scientific and medical competencies to support SKEZI team growth
- France ReinstrategicPartnership with leading kidney disease patient association to accelerate research and care evaluation using SKEZIA for data collection and e-cohort monitoring
- Club des Jeunes Néphrologues (CJN)minorPartnership enabling all CJN members to access SKEZIA for independent studies and data collection to accelerate kidney disease research
- AGORiA SantéminorPartnership to improve healthcare through better health data exploitation, accelerating patient-reported data collection for AGORIA's health data warehouse
- UCB PharmastrategicPharmaceutical partner for SPOON study on generalized myasthenia gravis, funded by UCB to understand patient quality of life and treatment expectations
- BiogenstrategicNewPerSEPtion study on perceived value of natalizumab treatment in multiple sclerosis patients, with SKEZI handling regulatory documents, data collection platform, and analysis
- ISART DigitalminorStrategic partnership with gaming/animation school to integrate gamification into e-health solution, making data collection more engaging
- SOS HépatitesminorCo-construction of patient feedback collection and liver disease research, including 'Juin sans sucres ajoutés' initiative
- Alliance PEP SantéminorPartnership with national healthcare platform supporting patient and caregiver accompaniment through SKEZIA availability
- EntendsMoi (Verbatim.Care)strategicAcquisition of EntendsMoi platform (Verbatim.Care) in December 2024 to strengthen SKEZIA with patient verbatim analysis and NLP capabilities
- AP-HPcoreCo-founding partner and primary research institution behind ComPaRe and ESPERES cohorts, largest hospital system in Europe
Scale indicators6 records
Recent moves7 records
Expansion highlights7 records
Skezi competitors and assessment
Company assessmentRegional players
- Doctolib: Doctolib is the dominant French health-tech platform used by hospitals and physicians; it is not a direct eCOA competitor but shapes the French procurement landscape in which SKEZI sells its interoperable e-health platform.
Broad incumbents
- Clario: Clario (formerly ERT/Bioclinica) is a large incumbent in clinical trial endpoint technology, including eCOA — providing the bundled alternative SKEZI competes against for hospital and pharma trials.
- Cegedim: Cegedim is a French health-data and clinical-research software incumbent (THINK, Clinityx) operating across real-world evidence and hospital information systems — overlapping with SKEZI's hospital interoperability play.
- Medidata (Dassault Systèmes): Medidata's Rave platform bundles EDC, eCOA, and patient-reported outcomes in one enterprise stack, making it the dominant broad incumbent competing for the same pharma-sponsored PRO data workloads.
Direct peers
- Signant Health: Signant Health is a global eCOA/ePRO specialist focused on patient-reported outcomes in clinical trials — the same core problem SKEZI addresses, with deeper enterprise pharma coverage.
- Castor: Castor is a direct competitor in eCOA/ePRO and electronic data capture for clinical trials, offering a self-service clinical research platform widely adopted by academic and commercial sponsors — directly overlapping SKEZI's SKEZIA offering.
Emerging players
- THREAD: THREAD is a decentralized clinical trial platform with eCOA/ePRO modules — overlapping SKEZI's decentralized patient data collection, though focused on global pharma rather than French institutional cohorts.
- Alira Health: Alira Health provides patient-centric real-world evidence and outcomes services for medtech and pharma — overlapping SKEZI's PRO/ePRO-based evidence generation value proposition.
- Owkin: Owkin is a French health-AI company working on real-world patient data for research — thematically adjacent to SKEZI's cohort and RWE focus within the French health-data ecosystem.
- Curebase: Curebase runs decentralized and hybrid clinical trials with built-in ePRO/eCOA, an emerging alternative for sponsors comparing site-less trial designs against e-cohort-based approaches like SKEZIA.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat6 records
Key risks4 records
Key highlights6 records
Customer concentration
Skezi social profiles
Digital presenceSkezi compliance and trust
Trust signalCompliance1 record
Skezi financial estimates
Financial estimateRevenue estimate
Valuation estimate
Skezi leadership team
Management profileNumber of profiles
Profiles3 records
Skezi subsidiaries and ownership
Company hierarchySubsidiaries2 records
Skezi funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Skezi M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Skezi
What does Skezi do?
Skezi (commercial name: SKEZI) sells the SKEZIA SaaS platform, a sovereign French health data collection solution that enables clinical researchers, healthcare institutions, pharmaceutical companies, and patient associations to build and manage electronic patient cohorts (e-cohorts) and collect patient-reported outcomes (PROMs/PREMs) via customizable questionnaires. The company complements SKEZIA with SKEMEET tele-expertise software, SKETHIS quality-of-life observatory services, and Verbatim.Care NLP-based patient verbatim analysis.
Is Skezi a public or private company?
Skezi is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Skezi founded?
Skezi was founded in 2020. It employs 11 to 50 people.
Where is Skezi based?
Skezi is headquartered in Annecy, France, in the Europe region.
How does Skezi make money?
Three revenue lines are on record. Software Subscriptions (SKEZIA/SKEMEET) is the primary driver. The others are professional Services and SKEZIA+ Service.
Who are Skezi's main competitors?
Doctolib is listed as a regional player. Broad incumbents are Clario, Cegedim and Medidata (Dassault Systèmes). Direct peers are Signant Health and Castor. Emerging players are THREAD, Alira Health, Owkin and Curebase.
Does Skezi have an API?
Yes. SKEZI announced the deployment of its API to make SKEZIA interoperable with all healthcare software in the hospital environment. This enables SKEZIA to connect with hospital information systems for streamlined data collection. No further technical details (REST/GraphQL, authentication, rate limits, versioning, sandbox) are publicly specified.
What industry is Skezi in?
Skezi's product category is Clinical Research Software (Health Data Collection & E-Cohort Management). Its primary akta.pro industry code is HLACAOAB, eCOA/ePRO/eDiary & Patient-Facing Data Collection, with a secondary code of HLAGACAH, Decentralized & Hybrid Trial Site Services (Home Health/Nursing). Its NAICS code is 5417 and its SIC code is 8090.